SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
---------------
FORM 10-QSB
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2001
Commission File No. 1-11182
BIO-IMAGING TECHNOLOGIES, INC.
-----------------------------------------------------------------
(Exact Name of Small Business Issuer as Specified in Its Charter)
Delaware 11-2872047
------------------------------- ------------------------------------
(State or Other Jurisdiction of (I.R.S. Employer Identification No.)
Incorporation or Organization)
826 Newtown-Yardley Rd., Newtown, PA 18940 08628-1020
--------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(267) 757-1360
---------------------------
(Issuer's Telephone Number,
Including Area Code)
Check whether the Issuer: (1) filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12
months (or for such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the past 90
days.
Yes: X No:
----- -----
State the number of shares outstanding of each of the Issuer's classes of
common stock, as of March 31, 2001:
Class Number of Shares
----- ----------------
Common Stock, $.00025 par value 8,190,545
Transitional Small Business Disclosure Format (check one):
Yes: No: X
----- -----
BIO-IMAGING TECHNOLOGIES, INC. AND SUBSIDIARIES
-----------------------------------------------
TABLE OF CONTENTS
-----------------
Page
----
PART I. FINANCIAL INFORMATION.
Item 1. Financial Statements...................................... 1
CONSOLIDATED BALANCE SHEETS
as of March 31, 2001 and
September 30, 2000 (unaudited).................................. 2
CONSOLIDATED STATEMENTS OF OPERATIONS
For the Six Months Ended March 31, 2001 and 2000
(unaudited)..................................................... 3
CONSOLIDATED STATEMENTS OF OPERATIONS
For the Three Months Ended March 31, 2001 and 2000
(unaudited)..................................................... 4
CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Six Months Ended March 31, 2001 and 2000
(unaudited)..................................................... 5
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (unaudited).......................................... 6
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations....................... 9
Results of Operations........................................... 10
Liquidity and Capital Resources................................. 14
PART II. OTHER INFORMATION.
Item 4. Submission of Matters to a Vote of Security Holders....... 16
Item 5. Other Information......................................... 17
Item 6. Exhibits and Reports on Form 8-K.......................... 17
SIGNATURES................................................................ 18
-i-
PART I. FINANCIAL INFORMATION.
------------------------------
ITEM 1. FINANCIAL STATEMENTS.
Certain information and footnote disclosures required under generally
accepted accounting principles have been condensed or omitted from the following
consolidated financial statements pursuant to the rules and regulations of the
Securities and Exchange Commission, although Bio-Imaging Technologies, Inc. (the
"Company") believes that such financial disclosures are adequate so that the
information presented is not misleading in any material respect. The following
consolidated financial statements should be read in conjunction with the
year-end consolidated financial statements and notes thereto included in the
Company's Annual Report on Form 10-KSB for the fiscal year ended September 30,
2000.
The results of operations for the interim periods presented herein are not
necessarily indicative of the results to be expected for the entire fiscal year.
-1-
BIO-IMAGING TECHNOLOGIES, INC. AND SUBSIDIARIES
-----------------------------------------------
CONSOLIDATED BALANCE SHEETS
---------------------------
(unaudited)
-----------
March 31, September 30,
2001 2000
----------- -------------
ASSETS
Current assets:
Cash and cash equivalents................................ $ 561,254 $ 491,048
Accounts receivable, net................................. 1,762,647 1,627,457
Prepaid expenses and other current assets................ 286,945 234,201
------------ ------------
Total current assets................................... 2,610,846 2,352,706
Property and equipment, net................................. 1,128,454 1,292,344
Other assets ............................................... 255,245 261,762
------------ ------------
Total assets........................................... $ 3,994,545 $ 3,906,812
============ ============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable......................................... $ 267,254 $ 321,113
Accrued expenses and other current liabilities........... 291,436 229,354
Deferred revenue......................................... 1,598,660 1,707,681
Current maturities of long-term debt..................... 155,582 150,796
------------ ------------
Total current liabilities.............................. 2,312,932 2,408,944
Long-term debt.............................................. 85,993 164,139
------------ ------------
Total liabilities...................................... 2,398,925 2,573,083
------------ ------------
Stockholders' equity:
Preferred stock - $.00025 par value; authorized
3,000,000 shares, issued and outstanding, 0 shares
at March 31, 2001, and 416,667 shares ($500,000
liquidation preference) at September 30, 2000........... -- 104
Common stock - $.00025 par value; authorized
18,000,000 shares, issued and outstanding
8,190,545 shares at March 31, 2001 and
7,773,878 shares at September 30, 2000.................. 2,048 1,944
Additional paid-in capital............................... 9,231,497 9,231,497
Accumulated deficit...................................... (7,637,925) (7,899,816)
------------ ------------
Stockholders' equity................................... 1,595,620 1,333,729
------------ ------------
Total liabilities and stockholders' equity............. $ 3,994,545 $ 3,906,812
============ ============
See Notes to Consolidated Financial Statements
-2-
BIO-IMAGING TECHNOLOGIES, INC. AND SUBSIDIARIES
-----------------------------------------------
CONSOLIDATED STATEMENTS OF OPERATIONS
-------------------------------------
(unaudited)
For the Six Months Ended
March 31,
-------------------------------------
2001 2000
---- ----
Project revenues............................................ $ 3,907,834 $ 2,540,499
------------ ------------
Cost and expenses:
Cost of revenues........................................ 2,037,416 1,652,499
General and administrative expenses..................... 784,295 621,412
Sales and marketing expenses............................ 805,297 696,406
------------ -----------
Total cost and expenses..................................... 3,627,008 2,970,317
------------ -----------
Income (loss) from operations............................... 280,826 (429,818)
Interest expense - net...................................... (8,935) (20,356)
------------ -----------
Net income (loss)........................................... 271,891 (450,174)
Dividends on preferred stock................................ 10,000 20,000
------------ -----------
Net income (loss) applicable to common stock................ $ 261,891 $ (470,174)
============ ===========
Basic earnings (loss) per common share...................... $ 0.03 $ (0.06)
============ ===========
Weighted average number of common shares.................... 7,976,456 7,773,878
============ ===========
Diluted earnings (loss) per common share.................... $ 0.03 $ (0.06)
============ ===========
Weighted average number of common
shares and dilutive common equivalent shares.............. 8,079,676 7,773,878
============ ===========
See Notes to Consolidated Financial Statements
-3-
BIO-IMAGING TECHNOLOGIES, INC. AND SUBSIDIARIES
-----------------------------------------------
CONSOLIDATED STATEMENTS OF OPERATIONS
-------------------------------------
(unaudited)
For the Three Months Ended
March 31,
--------------------------------------
2001 2000
---- ----
Project revenues............................................ $ 2,132,694 $ 1,462,545
------------ ------------
Cost and expenses:
Cost of revenues........................................ 1,054,183 947,086
General and administrative expenses..................... 445,279 303,268
Sales and marketing expenses............................ 413,044 346,579
------------- ------------
Total cost and expenses..................................... 1,912,506 1,596,933
------------ ------------
Income (loss) from operations............................... 220,188 (134,388)
Interest expense - net...................................... (1,006) (15,712)
------------ ------------
Net income (loss)........................................... 219,182 (150,100)
Dividends on preferred stock................................ -- 10,000
------------ ------------
Net income (loss) applicable to common stock................ $ 219,182 $ (160,100)
============ ============
Basic earnings (loss) per common share...................... $ 0.03 $ (0.02)
============ ============
Weighted average number of common shares.................... 8,190,545 7,773,878
============ ============
Diluted earnings (loss) per common share.................... $ 0.03 $ (0.02)
============ ============
Weighted average number of common
shares and dilutive common equivalent shares.............. 8,307,506 7,773,878
============ ============
See Notes to Consolidated Financial Statements
-4-
BIO-IMAGING TECHNOLOGIES, INC. AND SUBSIDIARIES
-----------------------------------------------
CONSOLIDATED STATEMENTS OF CASH FLOWS
-------------------------------------
(unaudited)
For the Six Months Ended
March 31,
----------------------------------
2001 2000
---- ----
Cash flows from operating activities:
Net income (loss) .................................................. $ 271,891 $ (450,174)
Adjustments to reconcile net income (loss) to net cash
provided by (used in) operating activities:
Depreciation and amortization..................................... 262,374 258,159
Changes in operating assets and liabilities:
Increase in accounts receivable................................. (135,190) (550,757)
Increase in prepaid expenses and other current assets........... (52,744) (8,116)
Decrease (increase) in other assets............................. 6,517 (1,311)
(Decrease) increase in accounts payable......................... (43,859) 242,868
Increase (decrease) in accrued expenses and other current
liabilities................................................... 62,082 (62,933)
(Decrease) increase in deferred revenue......................... (109,021) 76,615
----------- -----------
Net cash provided by (used in) operating activities............. 262,050 (495,649)
----------- -----------
Cash flows from investing activities:
Purchases of property and equipment................................. (98,484) (164,585)
----------- -----------
Net cash used in investing activities........................... (98,484) (164,585)
----------- -----------
Cash flows from financing activities:
Payments on equipment lease obligations and notes payable........... (73,360) (282,539)
Dividends paid to preferred stockholders............................ (20,000) (20,000)
Proceeds from notes payable......................................... -- 632,014
----------- -----------
Net cash (used in) provided by financing activities............. (93,360) 329,475
----------- -----------
Net increase (decrease) in cash and cash equivalents................... 70,206 (330,759)
Cash and cash equivalents at beginning of period....................... 491,048 412,903
----------- -----------
Cash and cash equivalents at end of period............................. $ 561,254 $ 82,144
=========== ===========
Supplemental disclosures of cash flow information:
Cash paid during the year for interest.............................. $ 15,606 $ 19,862
=========== ===========
Supplemental Schedule of noncash investing and financing activities:
Equipment purchased under capital lease obligations................. $ -- $ 251,864
=========== ===========
See Notes to Consolidated Financial Statements
-5-
BIO-IMAGING TECHNOLOGIES, INC. AND SUBSIDIARIES
-----------------------------------------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
------------------------------------------
(unaudited)
Note 1 - Basis of Presentation:
The financial statements included herein have been prepared by the Company,
without audit, pursuant to the rules and regulations of the Securities and
Exchange Commission. Certain information and footnote disclosures normally
included in financial statements prepared in accordance with generally accepted
accounting principles have been condensed or omitted pursuant to such rules and
regulations. These consolidated financial statements should be read in
conjunction with the consolidated financial statements and notes thereto
included in the Company's Annual Report on Form 10-KSB for the year ended
September 30, 2000.
In the opinion of the Company's management the accompanying unaudited
consolidated financial statements contain all adjustments, consisting solely of
those which are of a normal recurring nature, necessary to present fairly its
financial position as of March 31, 2001 and the results of its operations and
its cash flows for the six months ended March 31, 2001 and 2000 and the results
of its operations for the three months ended March 31, 2001 and 2000.
Interim results are not necessarily indicative of results for the full
fiscal year.
Basic earnings (loss) per common share was calculated based upon the net
earnings (loss) available to common stockholders divided by the weighted average
number of shares of common stock outstanding during the period. Diluted loss per
common share for the three months ended March 31, 2000 and six months ended
March 31, 2000 exclude the impact of convertible preferred stock, options
(1,430,775 as of March 31, 2000) and warrants (66,667 as of March 31, 2000) as
their inclusion would be antidilutive.
-6-
BIO-IMAGING TECHNOLOGIES, INC. AND SUBSIDIARIES
-----------------------------------------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
------------------------------------------
(unaudited)
Note 1 - Basis of Presentation: (continued)
The computation of basic earnings (loss) per common share and diluted
earnings (loss) per common share were as follows:
Six Months Ended Three Months Ended
March 31, March 31,
----------------------------- -----------------------------
2001 2000 2001 2000
------------ ------------ ------------ ------------
Net income (loss)................... $ 271,891 $ (450,174) $ 219,182 $ (150,100)
Dividends on preferred stock........ (10,000) (20,000) -- (10,000)
----------- ----------- ----------- -----------
Net income (loss) applicable
to common stock - basic.......... $ 261,891 $ (470,174) $ 219,182 $ (160,100)
----------- ----------- ----------- -----------
Dilutive dividends on preferred
stock.............................. 10,000 -- -- --
----------- ----------- ----------- -----------
Net income (loss) applicable
to common stock - diluted.......... $ 271,891 $ (470,174) $ 219,182 $ (160,100)
----------- ----------- ----------- -----------
Denominator:
Weighted average number of
common shares...................... 7,976,456 7,773,878 8,190,545 7,773,878
Basic earnings (loss) per
common share....................... $ 0.03 $ (0.06) $ 0.03 $ (0.02)
=========== =========== =========== ===========
Denominator:
Weighted average number of
common shares...................... 7,976,456 7,773,878 8,190,545 7,773,878
Common share equivalents of
outstanding stock options and
warrants........................... 103,220 -- 116,961 --
----------- ----------- ----------- -----------
Total shares........................ 8,079,676 7,773,878 8,307,506 7,773,878
----------- ----------- ----------- -----------
Diluted earnings (loss) per
common share....................... $ 0.03 $ (0.06) $ 0.03 $ (0.02)
=========== =========== =========== ===========
-7-
BIO-IMAGING TECHNOLOGIES, INC. AND SUBSIDIARIES
-----------------------------------------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
------------------------------------------
(unaudited)
Note 2 - Stockholders' Equity:
On January 2, 2001, the Company elected to convert the 416,667 shares of
its Series A Convertible Preferred Stock, $.00025 par value per share (the
"Series A Stock"), held of record by Investment Partners of America, L.P.
("IPA") into 416,667 shares of its restricted common stock, $.00025 par value
per share (the "Common Stock"). The shares of Common Stock issued upon
conversion of the Series A Stock were issued to the designees of IPA and have
certain piggy-back registration rights. The Company has satisfied any and all
obligations with respect to cumulative dividends on the Series A Stock. The
Company did not receive any consideration for the conversion of the Series A
Stock. Subsequent to the conversion, the Company has no issued and outstanding
shares of Series A Stock.
The Company has neither paid nor declared dividends on its Common Stock
since its inception and does not plan to pay dividends on its Common Stock in
the foreseeable future.
Note 3 - Long-term Debt:
During the six months ended March 31, 2001, the Company did not assign any
accounts receivables under the accounts receivable financing agreement with
Silicon Valley Bank. At March 31, 2001, the Company had no borrowings under the
accounts receivable financing agreement.
Note 4 - Recently Issued Accounting Standards:
In December 1999, the Securities and Exchange Commission issued Staff
Accounting Bulletin No. 101 ("SAB 101"), Revenue Recognition in Financial
Statements. SAB 101 provides guidance for revenue recognition under certain
circumstances. The accounting and disclosures prescribed by SAB 101 will be
effective for the fourth quarter of fiscal year 2001. The Company does not
believe that the application of SAB 101 will have a material impact on its
financial position or results of operations.
-8-
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.
OVERVIEW
Bio-Imaging Technologies, Inc. ("Bio-Imaging" or the "Company") is a
pharmaceutical contract service organization, providing services that support
the product development process of the pharmaceutical, biotechnology and medical
device industries. The Company specializes in assisting its clients in the
design and management of the medical-imaging component of clinical trials for
all modalities which consist of computerized tomography, magnetic resonance
imaging, x-rays, dual energy x-ray absorptiometry, position emission tomography
single photon emission computerized tomography and ultrasound. The Company
provides services which include the processing and analysis of medical images
and the data-basing and regulatory submission of medical images, quantitative
data and text. A new division of the Company, Bio-Imaging ETC, is focused on
education, training and certification for medical-imaging equipment, facilities
and staff.
The Company's sales cycle (the period from the presentation by the Company
to a potential client to the engagement of the Company by such client) is
generally twelve months. In addition, the contracts under which the Company
performs services typically cover a period of 12 to 36 months and the volume and
type of services performed by the Company generally vary during the course of a
project. No assurance can be made that the Company's project revenues will
remain at levels sufficient to maintain profitability. Project revenues were
generated from 47 clients encompassing 85 distinct projects for the six months
ended March 31, 2001 as compared to 33 clients encompassing 70 distinct projects
for the six months ended March 31, 2000. This represents an increase of 42.4% in
clients and 21.4% in projects for the six months ended March 31, 2001 as
compared to the six months ended March 31, 2000. The Company's
contracted/committed backlog was approximately $18,800,000 as of March 31, 2001
as compared to approximately $13,400,000 as of March 31, 2000, an increase of
40.3%. Contracted/committed backlog as of April 30, 2001, was approximately
$20,000,000. Contracted/committed backlog is the amount of revenue that remains
to be earned and recognized on signed and agreed to contracts. Such contracts
are subject to termination by the Company's clients at any time.
The Company believes that demand for its services and technologies will
grow during the long-term as the use of digital technologies for data
acquisition and management increases in the radiology and drug development
communities. The Company also believes that there is a growing recognition
within the bio-pharmaceutical industry regarding the use of an independent
centralized core laboratory for analysis of medical-imaging data that is derived
from clinical trials and the rigorous regulatory requirements relating to the
submission of this data. In addition, the Food and Drug Administration ("FDA")
is gaining experience with electronic submissions and is continuing to develop
guidelines for computerized submission of data, including medical images.
Furthermore, the increased use of digital medical images in clinical trials,
especially for important drug classes such as anti-inflammatory, neurologic and
oncologic
-9-
therapeutics and diagnostic image agents, generate large amounts of image data
that will require processing, analysis, data management and submission services.
Due to several factors, including, without limitation, an increase in
competition, there can be no assurance that demand for the Company's services
and technologies will grow, sustain growth, or that additional revenue
generating opportunities will be realized by the Company.
Certain matters discussed in this Form 10-QSB are "forward-looking
statements" intended to qualify for the safe harbors from liability established
by the Private Securities Litigation Reform Act of 1995. Such forward-looking
statements may be identified by, among other things, the use of forward-looking
terminology such as "believes," "expects," "may," "will," "should," or
"anticipates" or the negative thereof or other variations thereon or comparable
terminology, or by discussions of strategy that involve risks and uncertainties.
In particular, the Company's statements regarding the demand for the Company's
services and technologies, growing recognition for the use of independent
centralized core laboratories, trends toward the outsourcing of imaging services
in clinical trials, realized return from the Company's marketing efforts and
increased use of digital medical images in clinical trials are examples of such
forward-looking statements. The forward-looking statements include risks and
uncertainties, including, but not limited to, the timing of revenues due to the
variability in size, scope and duration of projects, regulatory delays, clinical
study results which lead to reductions or cancellations of projects, and other
factors, including general economic conditions and regulatory developments, not
within the Company's control. The factors discussed herein and expressed from
time to time in the Company's filings with the Securities and Exchange
Commission could cause actual results and developments to be materially
different from those expressed in or implied by such statements. The
forward-looking statements are made only as of the date of this filing and the
Company undertakes no obligation to publicly update such forward-looking
statements to reflect subsequent events or circumstances.
RESULTS OF OPERATIONS
Six Months Ended March 31, 2001 and 2000
----------------------------------------
Project revenues for the six months ended March 31, 2001 and 2000 were
approximately $3,908,000 and $2,540,000, respectively, an increase of
approximately $1,368,000 or 53.9%. Project revenues for the six months ended
March 31, 2001 and 2000 were derived from 47 clients encompassing 85 distinct
projects and 33 clients encompassing 70 distinct projects, respectively. Two
clients encompassing five projects represented approximately 35.9% of the
Company's project revenues for the six months ended March 31, 2001. For the
comparable period last year, one client encompassing five projects represented
approximately 18.5% of the Company's project revenues. No other customers
accounted for more than 10% of project revenues for the six months ended March
31, 2001 and 2000. The increase in project revenues is primarily a result of the
increase in the number of clients and projects for which the Company was engaged
to perform services. This increase resulted primarily from the increase in the
Company's sales and marketing efforts over the past year. The Company's scope of
work in both
-10-
periods included medical imaging core laboratory services and image-based
information management services.
Cost of revenues for the six months ended March 31, 2001 and 2000 were
comprised of professional salaries and benefits and allocated overhead. Cost of
revenues for the six months ended March 31, 2001 and 2000 were approximately
$2,037,000 and $1,652,000, respectively, an increase of approximately $385,000
or 23.3%. This increase is attributable to an increase in staffing levels
required for project related tasks for the six months ended March 31, 2001 and
in anticipation of work to be performed on new contracts as compared to the same
period in the prior year.
The difference between project revenues and cost of revenues may fluctuate
as a percentage of project revenues based on the utilization of staff and the
mix of services provided by the Company to its clients during the comparable
periods. The increase in this percentage difference for the six months ended
March 31, 2001 from the comparable period in fiscal 2000 resulted from a higher
increase in project revenues as compared to a lower increase in project related
costs.
General and administrative expenses for each of the six months ended March
31, 2001 and 2000 consisted primarily of professional salaries and benefits,
depreciation and amortization, professional and consulting services, office rent
and corporate insurance. General and administrative expenses were approximately
$784,000 for the six months ended March 31, 2001 and approximately $621,000 for
the six months ended March 31, 2000. The increase during the six months ended
March 31, 2001 of approximately $163,000, or 26.2%, from the corresponding
fiscal 2000 period, is primarily attributable to more professional services
associated with general corporate matters.
Sales and marketing expenses for each of the six months ended March 31,
2001 and 2000 were comprised of direct sales and marketing costs, professional
salaries and benefits and allocated overhead. Sales and marketing expenses were
approximately $805,000 for the six months ended March 31, 2001 and approximately
$696,000 for the corresponding fiscal 2000 period. The increase during the six
months ended March 31, 2001 of approximately $109,000, or 15.7%, from the
corresponding fiscal 2000 period, resulted primarily from expenses associated
with increased marketing efforts and increased attendance at additional
conferences.
Total cost and expenses for each of the six months ended March 31, 2001 and
2000 consisted primarily of cost of revenues, general and administrative
expenses and sales and marketing expenses. The Company's cost and expenses were
approximately $3,627,000 for the six months ended March 31, 2001 and
approximately $2,970,000 for the corresponding period in fiscal 2000. Such
increase of approximately $657,000, or 22.1%, is due primarily to an increase in
staffing levels required to support an increase in revenues along with an
increase in the Company's sales and marketing efforts and an increase in
professional services associated with general corporate matters.
-11-
Net interest expense of approximately $9,000 for the six months ended March
31, 2001, resulted from interest expense incurred in connection with equipment
lease obligations offset in part by interest earned on cash balances. Net
interest expense of approximately $20,000 for the six months ended March 31,
2000 resulted from interest expense incurred in the assignment of accounts
receivable and interest expense incurred in connection with equipment lease
obligations.
The Company's net income for the six months ended March 31, 2001 was
approximately $272,000, while the Company had net loss of approximately $450,000
for the six months ended March 31, 2000. The Company's net income for the six
months ended March 31, 2001 was attributable primarily to increased revenues
associated with an increase in the number of clients and projects for which the
Company was engaged to perform services.
Three Months Ended March 31, 2001 and 2000
------------------------------------------
Project revenues for the quarters ended March 31, 2001 ("Second Quarter of
Fiscal 2001") and 2000 ("Second Quarter of Fiscal 2000") were approximately
$2,133,000 and $1,463,000, respectively, an increase of approximately $670,000
or 45.8%. The increase in project revenues is primarily a result of the increase
in the Company's sales and marketing efforts over the past year. Project
revenues for the Second Quarter of Fiscal 2001 and Fiscal 2000 were derived from
41 clients encompassing 75 distinct projects and 30 clients encompassing 56
distinct projects, respectively. Three clients encompassing 11 projects
represented approximately 45.2% of the Company's project revenues for the three
months ended March 31, 2001. For the comparable period last year, three clients
encompassing nine projects represented approximately 37.4% of the Company's
project revenues. No other customers accounted for more than 10% of project
revenues in each of the Second Quarter of Fiscal 2001 and Fiscal 2000. The
Company's scope of work in both periods included medical imaging core laboratory
services and image-based information management services.
Cost of revenues for each of the Second Quarter of Fiscal 2001 and Fiscal
2000 were comprised of professional salaries and benefits and allocated
overhead. Cost of revenues for the Second Quarter of Fiscal 2001 and Fiscal 2000
were approximately $1,054,000 and $947,000, respectively, an increase of
approximately $107,000 or 11.3%. This increase is attributable to an increase in
staffing levels required for project related tasks for the Second Quarter of
Fiscal 2001 and in anticipation of work to be performed on new contracts as
compared to the Second Quarter of Fiscal 2000.
The difference between project revenues and cost of revenues may fluctuate
as a percentage of project revenues based on the utilization of staff and the
mix of services provided by the Company to its clients during the comparable
periods. The increase in this percentage difference for the Second Quarter of
Fiscal 2001 from the Second Quarter of Fiscal 2000 resulted from a higher
increase in project revenues as compared to a lower increase in project related
costs.
-12-
General and administrative expenses for each of the Second Quarter of
Fiscal 2001 and Fiscal 2000 consisted primarily of professional salaries and
benefits, depreciation and amortization, professional and consulting services,
office rent and corporate insurance. General and administrative expenses were
approximately $445,000 for the Second Quarter of Fiscal 2001 and approximately
$303,000 for the Second Quarter of Fiscal 2000. The increase of approximately
$142,000, or 46.9%, is primarily attributable to more professional services
associated with general corporate matters.
Sales and marketing expenses for each of the Second Quarter of Fiscal 2001
and Fiscal 2000 were comprised of direct sales and marketing costs, professional
salaries and benefits and allocated overhead. Sales and marketing expenses were
approximately $413,000 for the Second Quarter of Fiscal 2001 and approximately
$347,000 for the Second Quarter of Fiscal 2000. The increase during Second
Quarter of Fiscal 2001 of approximately $66,000, or 19.0%, from the Second
Quarter of Fiscal 2000, resulted primarily from expenses associated with
increased marketing efforts and increased attendance at additional conferences.
Total cost and expenses for each of the Second Quarter of Fiscal 2001 and
Fiscal 2000 consisted primarily of cost of revenues, general and administrative
expenses and sales and marketing expenses. The Company's cost and expenses were
approximately $1,913,000 in the Second Quarter of Fiscal 2001 and approximately
$1,597,000 for the Second Quarter of Fiscal 2000. Such increase of approximately
$316,000, or 19.8%, is primarily due to an increase in professional services
associated with general corporate matters along with an increase in staffing
levels required for project related tasks and an increase in the Company's sales
and marketing efforts.
Net interest expense of approximately $1,000 during the Second Quarter of
Fiscal 2001, resulted from interest expense in connection with equipment lease
obligations offset in part by interest earned on cash balances. Net interest
expense of approximately $16,000 for the Second Quarter of Fiscal 2000 resulted
from interest expense incurred in the assignment of accounts receivable and
interest expense incurred in conjunction with equipment lease obligations.
The Company's net income for the Second Quarter of Fiscal 2001 was
approximately $219,000, while the Company had a net loss of approximately
$150,000 for the Second Quarter of 2000. The Company's net income for the Second
Quarter of Fiscal 2001 was attributable primarily to increased revenues
associated with an increase in the number of clients and projects for which the
Company was engaged to perform services.
-13-
LIQUIDITY AND CAPITAL RESOURCES
At March 31, 2001, the Company had cash and cash equivalents of
approximately $561,000. Working capital at March 31, 2001 was approximately
$298,000.
Net cash provided by operating activities for the six months ended March
31, 2001 was approximately $262,000 which includes changes in certain of the
Company's operating assets and liabilities. The net income of approximately
$272,000 and depreciation and amortization expense of approximately $262,000 was
offset by an increase in accounts receivable of approximately $135,000 and a
decrease in deferred revenue of approximately $109,000.
For the six months ended March 31, 2001, the Company invested approximately
$98,000 in capital and leasehold improvements. The Company currently anticipates
that capital expenditures for the remainder of fiscal 2001 will be approximately
$100,000. These expenditures represent additional upgrades in the Company's
networking, data storage and core laboratory capabilities along with similar
capital requirements for its European operations.
In December 2000, the Company paid to the holders of its Series A
Convertible Preferred Stock, $.00025 par value per share (the "Series A Stock"),
an aggregate amount of $20,000, which amount represented accrued cumulative
dividends for the period from July 1, 2000 through and including December 31,
2000.
During the six months ended March 31, 2001, the Company did not assign any
accounts receivables under the accounts receivable financing agreement with
Silicon Valley Bank (the "Bank"). At March 31, 2001, the Company had a $0
balance with the Bank.
In August 1999, the Company entered into an agreement with the Bank for a
revolving line of credit of up to $500,000 collaterized by the Company's assets.
Interest is payable at 1.50% over the bank's prime rate of interest. The
agreement requires the Company, among other things, to maintain minimum levels
of tangible net worth and certain minimum financial ratios. In October 1999, the
Bank notified the Company that it would not make any advances under the existing
line of credit until the Company provides sufficient evidence satisfactory to
the Bank of an improvement in the Company's operating, financial and liquidity
position. At such time, the Bank may consider permitting further advances
pursuant to the loan agreement.
The Company anticipates that its cash and cash equivalents of $561,254 as
of March 31, 2001, together with anticipated cash from operations, will be
sufficient to fund current working capital needs and capital requirements for at
least the next twelve months. There can be no assurance, however, that the
Company's operating results will achieve profitability on an annual basis in the
near future. The Company's past history of operating losses and together with
the risks associated with the Company's ability to gain new client contracts,
the variability of the timing of payments on existing client contracts and other
changes in the Company's operating assets and liabilities, may have a material
adverse affect on the Company's future liquidity. In connection therewith, the
Company may need to raise additional capital in the foreseeable future
-14-
from equity or debt sources in order to implement its business, sales or
marketing plans, take advantage of unanticipated opportunities (such as more
rapid expansion, acquisitions of complementary businesses or the development of
new services), to react to unforeseen difficulties (such as the decrease in the
demand for the Company's services or the timing of revenues due to a variety of
factors previously discussed) or to otherwise respond to unanticipated
competitive pressures. There can be no assurance that additional financing will
be available, if at all, on terms acceptable to the Company.
The Company's 2001 operating plans contain assumptions regarding revenue
and expenses. The achievement of the operating plan depends heavily on the
timing of work performed by the Company on existing projects and the ability of
the Company to gain and perform work on new projects. Project cancellation, or
delays in the timing of work performed by the Company on existing projects or
the inability of the Company to gain and perform work on new projects could have
an adverse impact on the Company's ability to execute its operating plan and
maintain adequate cash flow. In the event actual results do not meet the
operating plan, the Company's management believes it could execute contingency
plans to mitigate such effects. Such plans include additional financing, to the
extent available, through the accounts receivable financing agreement discussed
above. In addition, in November 2000, the members of the Board of Directors of
the Company, in their individual capacities, committed up to an aggregate amount
totaling $100,000 in the form of a short-term loan, through October 1, 2001, if
needed by the Company. Considering the cash on hand and based on the achievement
of the operating plan and management's actions taken to date, management
believes it has the ability to continue to generate sufficient cash to satisfy
its operating requirements in the normal course of business for the next 12
months. However, no assurance can be given that sufficient cash will be
generated from operations. The Company's cash balance was approximately $561,000
and $464,000 as of March 31, 2001 and April 30, 2001, respectively.
-15-
PART II. OTHER INFORMATION.
--------------------------
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
(a) The Annual Meeting of Stockholders of the Company (the "Meeting") was held
on February 23, 2001.
(b) The following is a list of all of the Directors of the Company who were
elected at the Meeting and whose term of office continued after the
Meeting:
Mark L. Weinstein
Jeffrey H. Berg, Ph.D.
Marc Berger, ChFC
David E. Nowicki, D.M.D.
Allan E. Rubenstein, M.D.
David M. Stack
James A. Taylor, Ph.D.
(c) There were present at the Meeting, in person or by proxy, 4,873,004 shares
of Common Stock out of a total number of 8,190,545 shares of Common Stock
issued and outstanding and entitled to vote at the Meeting.
(d) The results of the vote of the stockholders taken at the Meeting by ballot
and by proxy as solicited by the Company on behalf of the Board of
Directors were as follows:
(i) The results of the vote taken at the Meeting for the election of the
nominees for the Board of Directors of the Company were as follows:
Nominee For Withheld
--------------------------- -------------------- ---------------
Mark L. Weinstein 4,823,404 39,600
Jeffrey H. Berg, Ph.D. 4,823,404 39,600
Marc Berger, ChFC 4,823,404 39,600
David E. Nowicki, D.M.D. 4,823,404 39,600
Allan E. Rubenstein, M.D. 4,823,404 39,600
David M. Stack 4,823,404 39,600
James A. Taylor, Ph.D. 4,823,404 39,600
(ii) A vote was taken on the proposal to ratify the appointment of Arthur
Andersen LLP as independent auditors of the Company for the fiscal
year ending September 30, 2001. The results of the vote taken at the
Meeting with respect to such appointment were as follows:
For Against Abstain
------------------ ------------------ -----------------
4,846,004 17,500 9,500
-16-
ITEM 5. OTHER INFORMATION.
On January 2, 2001, the Company elected to convert the 416,667 shares of
its Series A Stock held of record by Investment Partners of America, L.P.
("IPA") into 416,667 shares of its restricted common stock, $.00025 par value
per share (the "Common Stock"). The shares of Common Stock issued upon
conversion of the Series A Stock were issued to the designees of IPA and have
certain piggy-back registration rights. The Company has satisfied any and all
obligations with respect to cumulative dividends on the Series A Stock. The
Company did not receive any consideration for the conversion of the Series A
Stock. The Company will not receive any of the proceeds from any sales of such
shares of Common Stock by IPA or its designees. Subsequent to the conversion,
the Company has no issued and outstanding shares of Series A Stock.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K.
(a) Exhibits.
None.
(b) Reports on Form 8-K.
None.
-17-
SIGNATURES
In accordance with the requirements of the Securities Exchange Act of 1934,
the registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
BIO-IMAGING TECHNOLOGIES, INC.
DATE: May 11, 2001 By: /s/ Mark L. Weinstein
------------------------------------------
Mark L. Weinstein, President, Chief
Executive Officer and Chief Financial
Officer
(Principal Executive Officer and Principal
Financial Officer)
DATE: May 11, 2001 By: /s/ Maria T. Kraus
------------------------------------------
Maria T. Kraus, Controller
(Principal Accounting Officer)
-18-